Mihiro Sunose
Janssen Pharmaceutica
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mihiro Sunose.
Bioorganic & Medicinal Chemistry Letters | 2012
Kathryn Bell; Mihiro Sunose; Katie Ellard; Andrew Cansfield; Jess Taylor; Warren Miller; Nigel Ramsden; Giovanna Bergamini; Gitte Neubauer
Herein we describe the SAR of a novel series of 6-aryl-2-amino-triazolopyridines as potent and selective PI3Kγ inhibitors. The 6-aryl-triazolopyridine core was identified by chemoproteomic screening of a kinase focused library. Rapid chemical expansion around a bi-functional core identified the key features required for PI3Kγ activity and selectivity. The series was optimized to afford 43 (CZC19945), a potent PI3Kγ inhibitor with high oral bioavailability and selectivity over PI3Kα and PI3Kδ. Modification to the core afforded 53 (CZC24832) which showed increased selectivity over the entire kinome in particular over PI3Kβ.
Bioorganic & Medicinal Chemistry Letters | 2012
Katie Ellard; Mihiro Sunose; Kathryn Bell; Nigel Ramsden; Giovanna Bergamini; Gitte Neubauer
Dual PI3Kγ/δ inhibitors have recently been shown to be suitable targets for inflammatory and respiratory diseases. In a recent study we described the discovery of selective PI3Kγ inhibitors based on a triazolopyridine scaffold. Herein, we describe the elaboration of this structural class into dual PI3Kγ/δ inhibitors with excellent selectivity over the other PI3K isoforms and the general kinome. Structural optimization led to the identification of two derivatives which showed significant efficacy in an acute model of lung inflammation.
ACS Medicinal Chemistry Letters | 2016
Andrew Cansfield; Tammy Ladduwahetty; Mihiro Sunose; Katie Ellard; Rosemary Lynch; Anthea L. Newton; Ann Lewis; Gavin Bennett; Nico Zinn; Douglas Thomson; Anne J. Rüger; John Thomas Feutrill; Oliver Rausch; Alan P. Watt; Giovanna Bergamini
CZ415, a potent ATP-competitive mTOR inhibitor with unprecedented selectivity over any other kinase is described. In addition to a comprehensive characterization of its activities in vitro, in vitro ADME, and in vivo pharmacokinetic data are reported. The suitability of this inhibitor for studying in vivo mTOR biology is demonstrated in a mechanistic mouse model monitoring mTOR proximal downstream phosphorylation signaling. Furthermore, the compound reported here is the first ATP-competitive mTOR inhibitor described to show efficacy in a semitherapeutic collagen induced arthritis (CIA) mouse model.
Archive | 2007
Francis X. Wilson; Nigel Ramsden; Kathryn Bell; Andrew Cansfield; Svenja Burckhardt; Jess Taylor; Mihiro Sunose; David Middlemiss
Archive | 2008
Nigel Ramsden; Kathryn Bell; Andrew Cansfield; Jess Taylor; Mihiro Sunose; David Middlemiss; Gitte Neubauer
Archive | 2010
Nigel Ramsden; Jeremy Major; Adeline Morel; Mihiro Sunose; Nelly Piton
Archive | 2010
Mihiro Sunose; Jeremy Major; Richard John Harrison; Jay Freeman; Adeline Morel
Archive | 2007
Francis Wilson; Alison Reid; Valerie Reader; Richard John Harrison; Mihiro Sunose; Remedios Hernadez-Perni; Jeremy Major; Cyrille Boussard; Kathryn Smelt; Jess Taylor; Adeline Leformal; Andrew Cansfield; Svenja Burckhardt; Yan Zhang; Chih Yung Ho
Archive | 2007
Francis Wilson; Alison Reid; Valerie Reader; Richard John Harrison; Mihiro Sunose; Remedios Hernadez-Perni; Jeremy Major; Cyrille Boussard; Kathryn Smelt; Jess Taylor; Adeline Leformal; Andrew Cansfield; Svenja Burckhardt; Chih Yung Ho; Yan Zhang
Archive | 2005
Francis X. Wilson; Alison Reid; Valerie Reader; Richard John Harrison; Mihiro Sunose; Remedios Hernandez-Perni; Jeremy Major; Cyrille Boussard; Kathryn Smelt; Jess Taylor; Adeline Leformal; Andrew Cansfield; Svenja Burckhardt